What's New for MGH Inpatient eMAR & Order Entry?

May 21, 2013—Chemotherapy Warning: Maximum Lifetime Cumulative Dose

Providers writing new orders for anthracyclines are notified automatically if the dose they are writing pushes the patient’s lifetime cumulative dose to equal or exceed the maximum lifetime dose for that medication.

Key features:

• Lifetime dosing is monitored for all Dana Farber Partners Cancer Care (DFPCC) sites—MGH inpatient and ambulatory, Dana Farber (DFCI), and BWH inpatient and ambulatory locations

• Historical orders include activated orders only—no orders awaiting activation

• Anthracyclines monitored include Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, and Mitoxantrone for adult and pediatric patients, and Bleomycin for pediatric patients only

• Duplicates, change to orders, and discontinue orders: if there is more than one activation for the same chemo medication, for the same date, the higher dose is displayed

More information:

• Responding to the Chemo Lifetime Maximum Dose Warning

• Evaluating Cumulative Dose Information

• Ordering Chemotherapy

• Overview of Writing Chemo Orders

See also:

• What’s new with the MGH eMAR?

• Archive of What's New for MGH Order Entry